Commercialization of Rapid Drug Susceptibility Testing Through an Investment in Astrego
First written in FY2020. 4 of 7 entries say "Advanced", first in FY2021. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「We launched in Europe a rapid antimicrobial susceptibility testing system that uses urine samples from patients suspected of having urinary tract infections to determine the presence of bacteria and the effectiveness of antibiotics in as little as approximately 30 minutes after measurement begins.」
The European launch of Astrego’s rapid antimicrobial susceptibility testing system and its shortest approximately 30-minute determination time have been reposted. - FY2024-Q1AdvancedAnnual report
「June 2023: We launched in Europe a rapid antimicrobial susceptibility testing system that uses urine samples from patients suspected of having urinary tract infections to determine the presence of bacteria and the effectiveness of antibiotics in as little as approximately 30 minutes after measurement begins.」
Astrego’s rapid antimicrobial susceptibility test was launched in Europe, and its shortest approximately 30-minute determination time using proprietary microfluidic technology was put into practical use. - FY2023RestatedAnnual report
「In May 2022, to accelerate the clinical implementation of rapid antimicrobial susceptibility testing for urinary tract infections and contribute to addressing medical challenges, including efforts to combat antimicrobial resistance (AMR), the Company acquired additional shares of its equity-method affiliate Astrego Diagnostics AB and made it a wholly owned subsidiary.」
The full-subsidiary conversion of Astrego and the acceleration of the clinical implementation of rapid antimicrobial susceptibility testing for urinary tract infections and AMR initiatives have been reposted as research and development activities. - FY2023-Q1AdvancedAnnual report
「In May 2022, to accelerate the clinical implementation of rapid antimicrobial susceptibility testing for urinary tract infections and contribute to addressing medical challenges, including efforts to combat antimicrobial resistance (AMR), the Company acquired additional shares of its equity-method affiliate Astrego Diagnostics AB and made it a wholly owned subsidiary.」
The initiative progressed from the investment in Astrego, with additional shares acquired in May 2022 and Astrego becoming a wholly owned subsidiary. The stated purpose is to accelerate the clinical implementation of rapid antimicrobial susceptibility testing for urinary tract infections and efforts to combat AMR. - FY2022AdvancedAnnual report
「The Company acquired additional shares of Astrego Diagnostics AB, hereinafter ADA. As a result, ADA will become a wholly owned subsidiary of the Company from the following consolidated fiscal year. The purpose of the acquisition is to further strengthen synergies with ADA in urinary tract infections and accelerate the clinical implementation of antimicrobial susceptibility testing.」
The initiative progressed from the investment in Astrego, with additional shares acquired on 2 May 2022 and ADA becoming a wholly owned subsidiary from the following consolidated fiscal year. The purpose is to accelerate the clinical implementation of antimicrobial susceptibility testing for urinary tract infections. - FY2021AdvancedAnnual report
「Investment in Astrego Diagnostics AB toward developing a new urinalysis solution for the primary care business」
The initiative progressed from the agreement to invest in Astrego to the investment being made in June 2020. - FY2020First statedAnnual report
「In January 2020, the Company and Astrego Diagnostics AB, hereinafter Astrego, agreed that the Company would invest in Astrego to commercialize the rapid antimicrobial susceptibility test for urinary tract infections that Astrego was developing.」
Through its agreement to invest in Astrego, the Company launched a new initiative aimed at commercializing rapid antimicrobial susceptibility testing for urinary tract infections.